Eve Tirzepatide Review: Cost, Women's-Health Focus & Honest Verdict (2026)

Eve: $195/month for tirzepatide, and genuine brand-name mentions of Ozempic, Wegovy, and Mounjaro on the site alongside its compounded offerings — a dual pathway that's rare in this category. Every fact here comes from the company's own published program.

What Eve is

Eve is a women's-health-focused GLP-1 telehealth platform — a genuinely distinctive positioning in a largely gender-neutral market, filling a real gap most competitors don't address. Brand-name Ozempic, Wegovy, and Mounjaro are referenced on the site alongside compounded semaglutide and tirzepatide.

What Eve costs

Tirzepatide runs $195/month. Eve also offers oral sublingual semaglutide alongside the injectable form, and publishes the FDA compounded-medication disclaimer on-site — a genuine transparency practice.

Both compounded and brand-name — a rare combination

Eve genuinely offers both compounded and brand-name FDA-approved options on one platform — a rare combination in this category, most of which force you to choose compounded-only or brand-only from the start.

What's undisclosed

Eve's full states-served list isn't published, its 503A pharmacy partner isn't named (and 503A vs. 503B status isn't specified), no named medical director or clinical leadership is disclosed, the corporate legal entity isn't disclosed, and governing law/arbitration venue isn't stated. LegitScript certification is claimed with a verifiable ID, though this review's live pass could not independently confirm that specific claim on the pages fetched.

The brand-vs-compounded question

Eve offers both compounded tirzepatide and a genuine brand-name pathway. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials; brand tirzepatide/semaglutide is the exact molecule and dose that was. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Eve's real strengths: a genuinely women's-health-focused positioning, both compounded and brand-name options, and an oral sublingual option and a published FDA compounded-medication disclaimer. The trade-offs: this review found no published state list, no named pharmacy partner, no named medical director, and no disclosed corporate legal entity or governing law. As with any GLP-1 program, ask directly about the compounding pharmacy and your state's coverage before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Eve's genuine women's-health focus and dual compounded-and-brand pathway are real differentiators this review but this review couldn't find a named pharmacy, medical director, or legal entity — ask directly before committing. If you want a similarly dual-pathway provider with more disclosed corporate detail, compare it against Concierge MD LA or Effecty. For another OB/GYN-led, women-focused practice, though with a much narrower 5-state footprint, see Gaya Wellness. And for a genuinely underserved niche of its own, see our Go Vida Plena review, a Spanish-first program built for Latino patients. See our best tirzepatide providers ranking for the full field.